Based on Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, Decision Resources is offering an exclusive analyst call entitled Which Biosimilar TNF-alpha Inhibitor Poses the Greatest Threat to Brand Sales? This analyst call is open ONLY to subscribers of this module of the Biosimilars Advisory Service.

Biosimilar immune biologics will erode $10.8 billion in immune biologics brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan. Competition between branded and biosimilar TNF-alpha inhibitors and pressure to reduce costs through biosimilars use will contribute to a substantial erosion of brand sales. Biosimilars’ anticipated lower costs compared with branded biologics will be a major driver of their use among both U.S. and European gastroenterologists and rheumatologists.

The Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German gastroenterologists and rheumatologists to highlight the key expectations that will drive or constrain biosimilar adoption.

Recorded live on Tuesday, October 5, 2010


This analyst call, presented by Decision Resources Analyst MaryEllen Klusacek, Ph.D., discusses building a market forecast from primary research findings and answers the following questions:

• What type of quantitative data informs our market forecast for TNF-alpha inhibitors?
• What will be the relative uptake of biosimilar TNF-alpha inhibitors and how does it compare with biosimilars in other drug classes?
• How will uptake of biosimilar TNF-alpha inhibitors vary by country and by brand?
• Which brand will be most affected by biosimilar erosion? 

Contact us to learn how you can purchase this service and access a recorded playback of this event.

Click here to view the invite.